Results 211 to 220 of about 24,787 (310)

OX40/OX40L modulation: A target for regulating T cells in cutaneous inflammatory disorders

Journal of the European Academy of Dermatology and Venereology, EarlyView.
OX40 and OX40L are a co‐stimulatory immune checkpoint pair. Modulation of this pair impacts multiple immune phenotypes and is an attractive target for immunotherapy in dermatological disorders. Trials are underway with the majority in atopic dermatitis and currently in phase 3 trials.
Aditya K. Gupta, Julia Steriopoulos, Vasiliki Economopoulos, Paradi Mirmirani, Vincent Piguet   +4 more
wiley   +1 more source

Vaccinating patients on biologics for atopic disease: Clinical considerations and evidence-based recommendations. [PDF]

Allergy Asthma Proc
Chase NM.
europepmc   +1 more source

Dupilumab and cutaneous T-cell lymphoma: A retrospective cohort study. [PDF]

JAAD Int
Baghdasarian S, Al-Saedi O, Cuomo RE.
europepmc   +1 more source

Dupilumab in moderate‐to‐severe prurigo nodularis: Real‐world data from early access program

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Marie Jachiet, Clémentine Toussaint, Valérie Dorizy‐Vuong, Sophie Osdoit, Pierre‐André Becherel, Emmanuelle Amazan, Julia Vanlerberghe, Mahtab Samimi, Claudia Soares Barbosa, Carine Vera, Simmi Wiggins, Véronique Marcadé Fulcrand, Cédric Meyer, Laurent Misery, Jean‐David Bouaziz   +14 more
wiley   +1 more source

Immune system benefits of pulmonary rehabilitation in chronic obstructive pulmonary disease

Experimental Physiology, EarlyView.
Abstract Chronic obstructive pulmonary disease (COPD) is a respiratory disease characterized by pulmonary and systemic inflammation. Inflammatory mediators show relationships with shortness of breath, exercise intolerance and health related quality of life. Pulmonary rehabilitation (PR), a comprehensive education and exercise training programme, is the
Asghar Abbasi, David Wang, William W. Stringer, Richard Casaburi, Harry B. Rossiter   +4 more
wiley   +1 more source

The evaluation of the plasma levels of interleukin 17A, thymic stromal lymphopoietin, interferon gamma, tumor necrosis factor-alpha and interleukins IL-2, IL-6, IL-23, and IL-31 in atopic dermatitis patients with dupilumab treatment. [PDF]

Front Immunol
Čelakovská J, Čermáková E, Boudkova P, Andrýs C.   +3 more
europepmc   +1 more source

Less Can Be Enough: Sustained Remission of Pediatric Eosinophilic Esophagitis With Low‐Frequency Dupilumab

Clinical Case Reports, Volume 14, Issue 5, May 2026.
ABSTRACT Eosinophilic esophagitis (EoE) is a chronic, immune‐mediated disease requiring long‐term therapy. Dupilumab, an interleukin‐4 and interleukin‐13 receptor antagonist, is approved for EoE at a weekly 300 mg dosing regimen. However, data on reduced‐frequency dosing, especially in pediatric patients, remain limited.
Giovanni Scatigna, Annarita Iadecola, Martina Piersanti, Giovanni Di Nardo, Maurizio Mennini   +4 more
wiley   +1 more source

Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials.

JAMA Dermatol
Casale TB, Saini SS, Ben-Shoshan M, Giménez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M.   +12 more
europepmc   +1 more source

Dupilumab Improves Daily Symptom Burden in Adult Patients with Prurigo Nodularis: Post Hoc Analysis from LIBERTY PN-PRIME and PRIME2 Studies. [PDF]

Dermatol Ther (Heidelb)
Kwatra SG, Ständer S, Kim BS, Msihid J, Bansal A, Makhija M, Wiggins S, Zahn J, Thomas RB, Bahloul D.   +9 more
europepmc   +1 more source

Impact of Lung Function on Asthma Exacerbation Rates in Children Treated with Dupilumab: The VOYAGE Study

Theresa W. Guilbert, Kevin R. Murphy, Eckard Hamelmann, Kristie Ross, Atul Gupta, Alessandro Fiocchi, Changming Xia, Rebecca Gall, Olivier Ledanois, Amr Radwan, Juby A. Jacob‐Nara, Paul J. Rowe, Yamo Deniz   +12 more
openalex   +2 more sources